menu
    • menu

    Company profile for CeleCor Therapeutics

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Each year, more than 1.2 million Americans suffer a heart attack, one of the top three leading causes of death in the United States. PCI for serious heart attacks (ST-segment Elevated Myocardial Infarction or STEMI). PCI has greatly improved outcomes and emphasized the importance of initiating therapy as rapidly as possible, leading to major efforts to shorten the door to balloon time. Although the risk of dying of a heart a...
    Each year, more than 1.2 million Americans suffer a heart attack, one of the top three leading causes of death in the United States. PCI for serious heart attacks (ST-segment Elevated Myocardial Infarction or STEMI). PCI has greatly improved outcomes and emphasized the importance of initiating therapy as rapidly as possible, leading to major efforts to shorten the door to balloon time. Although the risk of dying of a heart attack while in the hospital has decreased dramatically over the past four decades, pre-hospital treatment and subsequent mortality remains essentially unchanged.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CeleCor TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1155 Camino Del Mar #481DELDel Mar, CA 92014
    Telephone
    Telephone
    858-777-9750
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.celecor.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Harrington Support Advances Heart Attack Drug to Clinical Trials
    Harrington Support Advances Heart Attack Drug to Clinical Trials

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/support-from-harrington-discovery-institute-at-university-hospitals-helped-advance-heart-attack-drug-into-clinical-trials-302614670.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share
    Zalunfiban At First Contact Reduced Severe Heart Damage Risk
    Zalunfiban At First Contact Reduced Severe Heart Damage Risk

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rapid-zalunfiban-treatment-at-1st-point-of-medical-contact-lowered-risk-of-more-severe-heart-damage-in-combination-with-other-serious-heart-attack-complications-302608665.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    Novel Anti-Platelet Drug Phase 3 Study For Heart Attack Shows
    Novel Anti-Platelet Drug Phase 3 Study For Heart Attack Shows

    23 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/phase-3-study-of-novel-anti-platelet-drug-for-heart-attack-reports-positive-topline-results-302563949.html

    PR NEWSWIRE
    23 Sep 2025
    Share Share
    Celecor Finishes Multinational Phase 3 Study of Heart Attack
    Celecor Finishes Multinational Phase 3 Study of Heart Attack

    27 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/celecor-completes-multinational-phase-3-registrational-study-of-novel-anti-platelet-agent-for-heart-attack-302464566.html

    PR NEWSWIRE
    27 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search